title: Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?
abstract: The antitumor effect of bisphosphonates (BPs) is under increasing scrutiny. Preclinical and clinical evidence has shown that BPs might sensitize breast tumors to chemotherapy. Here, we present a review of current preclinical and clinical evidence for antitumor effects of BPs, and evaluate how BPs might play a role in neoadjuvant treatment of women with breast cancer.
authors.affiliation: Department of Surgery, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. a.charehbili@lumc.nl.|Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. a.charehbili@lumc.nl.
authors.forename: Ayoub
authors.initials: A
authors.lastname: Charehbili
authors.affiliation: Department of Surgery, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. d.b.y.fontein@lumc.nl.
authors.forename: Duveken B Y
authors.initials: DB
authors.lastname: Fontein
authors.affiliation: Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. j.r.kroep@lumc.nl.
authors.forename: Judith R
authors.initials: JR
authors.lastname: Kroep
authors.affiliation: Department of Surgery, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. g.j.liefers@lumc.nl.
authors.forename: Gerrit-Jan
authors.initials: GJ
authors.lastname: Liefers
authors.affiliation: Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. j.w.r.nortier@lumc.nl.
authors.forename: Johannes W R
authors.initials: JW
authors.lastname: Nortier
authors.affiliation: Department of Surgery, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands. c.j.h.van_de_velde@lumc.nl.
authors.forename: Cornelis J H van de
authors.initials: CJ
authors.lastname: Velde
keywords: bisphosphonates; chemotherapy; neoadjuvant; postmenopausal; zoledronic acid